Upsher-Smith has acquired US and other territory rights to two specialty product assets of Dr Reddy’s, which appears to be tweaking the commercialization approach of its proprietary products business.
Upsher-Smith Laboratories LLC, a subsidiary of major Japanese generics company Sawai Pharmaceutical Co. Ltd., has snapped up US and select territory rights to two migraine assets from India's Dr. Reddy's Laboratories Ltd. for over $110m, bolstering its portfolio in the specialty segment.
The two products, Zembrace Symtouch (sumatriptan injection) 3mg and Tosymra (sumatriptan nasal spray) 10mg, which are part of Dr Reddy’s proprietary portfolio, were commercialized in the US via the Indian
Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.
BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.
A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.
